NUVB Fundamental Analysis - NUVATION BIO INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to NUVB. NUVB was compared to 192 industry peers in the Pharmaceuticals industry. NUVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, NUVB is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NUVB has reported negative net income.

In the past year NUVB has reported a negative cash flow from operations.

NUVB had negative earnings in each of the past 5 years.

In the past 5 years NUVB always reported negative operating cash flow.

1.2 Ratios

NUVB has a Return On Assets (-36.15%) which is comparable to the rest of the industry.

NUVB has a Return On Equity of -66.74%. This is comparable to the rest of the industry: NUVB outperforms 45.83% of its industry peers.

		Industry Rank	Sector Rank
ROA	-36.15%
ROE	-66.74%
ROIC	N/A

ROA(3y)-44.25%

ROA(5y)-34.58%

ROE(3y)-50.3%

ROE(5y)-38.48%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NUVB has a better Gross Margin (54.26%) than 65.63% of its industry peers.

The Profit Margin and Operating Margin are not available for NUVB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	54.26%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NUVB does not have a ROIC to compare to the WACC, probably because it is not profitable.

NUVB has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, NUVB has more shares outstanding

The debt/assets ratio for NUVB is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 4.32 indicates that NUVB is not in any danger for bankruptcy at the moment.

NUVB has a Altman-Z score of 4.32. This is in the better half of the industry: NUVB outperforms 72.40% of its industry peers.

NUVB has a Debt/Equity ratio of 0.61. This is a neutral value indicating NUVB is somewhat dependend on debt financing.

NUVB has a Debt to Equity ratio of 0.61. This is in the lower half of the industry: NUVB underperforms 67.19% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.61
Debt/FCF	N/A
Altman-Z	4.32

ROIC/WACCN/A

WACC9.39%

2.3 Liquidity

A Current Ratio of 8.48 indicates that NUVB has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 8.48, NUVB is in the better half of the industry, outperforming 75.00% of the companies in the same industry.

NUVB has a Quick Ratio of 8.39. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.

NUVB's Quick ratio of 8.39 is fine compared to the rest of the industry. NUVB outperforms 75.52% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.48
Quick Ratio	8.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for NUVB have decreased strongly by -48.84% in the last year.

The Revenue has grown by 1137.19% in the past year. This is a very strong growth!

EPS 1Y (TTM)-48.84%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-6.67%

Revenue 1Y (TTM)1137.19%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%1704.68%

3.2 Future

The Earnings Per Share is expected to grow by 53.75% on average over the next years. This is a very strong growth

NUVB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 202.28% yearly.

EPS Next Y-16.28%

EPS Next 2Y-0.31%

EPS Next 3Y15.7%

EPS Next 5Y53.75%

Revenue Next Year2424.31%

Revenue Next 2Y767.19%

Revenue Next 3Y406.27%

Revenue Next 5Y202.28%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NUVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NUVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NUVB's earnings are expected to grow with 15.70% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-0.31%

EPS Next 3Y15.7%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NUVB!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

NUVATION BIO INC

NYSE:NUVB (12/22/2025, 6:40:00 PM)

After market: 9.49 -0.05 (-0.52%)

9.54

+0.1 (+1.06%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-03 2025-11-03/amc

Earnings (Next)03-04 2026-03-04/amc

Inst Owners65.09%

Inst Owner Change-2.28%

Ins Owners17.92%

Ins Owner Change0%

Market Cap3.27B

Revenue(TTM)26.75M

Net Income(TTM)-217.48M

Analysts83.75

Price Target10.65 (11.64%)

Short Float %19.15%

Short Ratio5.82

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)3.93%

Min EPS beat(2)0.88%

Max EPS beat(2)6.98%

EPS beat(4)3

Avg EPS beat(4)0.55%

Min EPS beat(4)-6.56%

Max EPS beat(4)6.98%

EPS beat(8)5

Avg EPS beat(8)-11.26%

EPS beat(12)9

Avg EPS beat(12)-2.73%

EPS beat(16)12

Avg EPS beat(16)-0.14%

Revenue beat(2)2

Avg Revenue beat(2)660.6%

Min Revenue beat(2)94.49%

Max Revenue beat(2)1226.72%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)19.85%

PT rev (3m)39.26%

EPS NQ rev (1m)-2.11%

EPS NQ rev (3m)29.93%

EPS NY rev (1m)9.27%

EPS NY rev (3m)8.5%

Revenue NQ rev (1m)-4.78%

Revenue NQ rev (3m)83.66%

Revenue NY rev (1m)85.18%

Revenue NY rev (3m)63.95%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	122.27
P/FCF	N/A
P/OCF	N/A
P/B	10.04
P/tB	10.41
EV/EBITDA	N/A

EPS(TTM)-0.64

EYN/A

EPS(NY)-0.52

Fwd EYN/A

FCF(TTM)-0.58

FCFYN/A

OCF(TTM)-0.55

OCFYN/A

SpS0.08

BVpS0.95

TBVpS0.92

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-36.15%
ROE	-66.74%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	54.26%
FCFM	N/A

ROA(3y)-44.25%

ROA(5y)-34.58%

ROE(3y)-50.3%

ROE(5y)-38.48%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	0.61
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	581.54%
Cap/Sales	30.85%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.48
Quick Ratio	8.39
Altman-Z	4.32

F-Score4

WACC9.39%

ROIC/WACCN/A

Cap/Depr(3y)79.93%

Cap/Depr(5y)109.07%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-48.84%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-6.67%

EPS Next Y-16.28%

EPS Next 2Y-0.31%

EPS Next 3Y15.7%

EPS Next 5Y53.75%

Revenue 1Y (TTM)1137.19%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%1704.68%

Revenue Next Year2424.31%

Revenue Next 2Y767.19%

Revenue Next 3Y406.27%

Revenue Next 5Y202.28%

EBIT growth 1Y-73.28%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-186.24%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-174.8%

OCF growth 3YN/A

OCF growth 5YN/A

NUVATION BIO INC / NUVB FAQ

What is the ChartMill fundamental rating of NUVATION BIO INC (NUVB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NUVB.

What is the valuation status for NUVB stock?

ChartMill assigns a valuation rating of 0 / 10 to NUVATION BIO INC (NUVB). This can be considered as Overvalued.

How profitable is NUVATION BIO INC (NUVB) stock?

NUVATION BIO INC (NUVB) has a profitability rating of 1 / 10.

What is the expected EPS growth for NUVATION BIO INC (NUVB) stock?

The Earnings per Share (EPS) of NUVATION BIO INC (NUVB) is expected to decline by -16.28% in the next year.

NUVATION BIO INC (NUVB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NUVATION BIO INC / NUVB FAQ

What is the ChartMill fundamental rating of NUVATION BIO INC (NUVB) stock?

What is the valuation status for NUVB stock?

How profitable is NUVATION BIO INC (NUVB) stock?

What is the expected EPS growth for NUVATION BIO INC (NUVB) stock?